PRESSRELEASE

SHIONOGI

Notice of Entering Into a Capital Alliance Agreement with LIFESCAPES

OSAKA, Japan, November 2, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi has concluded a capital alliance ("this capital alliance") with LIFESCAPES Inc. (Head Office: Tokyo, Japan; Chief Executive Officer: Junichi Ushiba, hereafter "LIFESCAPES").

LIFESCAPES has developed Brain-Machine Interface (BMI) technology, which forms the basis of their medical devices designed to assist in motor function recovery in severe stroke patients. Patients who have had a stroke often suffer from severe motor impairment and may require nursing care for an extended period. There is currently no effective treatment for severe movement disorders. Using BMI, LIFESCAPES has been aiming to enable patients to recover independent movement capability.

In this capital alliance, Shionogi will invest about 100 million yen in LIFESCAPES, to support their technology and product development to improve rehabilitation of severely paralyzed stroke patients, and to increase intercompany dialogue, sharing disease area knowledge and networks to the benefit of both companies.

Shionogi stated in its STS2030 business plan its Group Vision to create new healthcare platforms to meet the needs of patients and society, thereby by transforming ourselves into "a HaaS company" that provides comprehensive healthcare solutions addressing important unmet medical needs. As we continually refine our own capabilities, we will continue to work to address the healthcare needs of patients and society through an expanded network of collaborations with external partners.

【About LIFESCAPES】

LIFESCAPES established in May 2018 is a startup company arising from Keio University. With a mission to contribute to recovery of patients with severe paralysis, previously thought to be "a lifelong condition," LIFESCAPES develops technology that draws upon neural plasticity, creating innovative medical devices using brain-machine interface technology.

【About BMI】

BMI refers to the technology connecting the brain and machines, linking brain wave detection, electrical stimulation of the brain, and robotic-assisted movement

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html